FDA Grants Accelerated Approval to Epkinly for Relapsed or Refractory Follicular Lymphoma

The FDA has granted accelerated approval to Epkinly, a bispecific CD20-directed CD3 T-cell engager, for adult ...

JUNE 27, 2024